Search

As the COVID-19 pandemic continues, countries around the world are switching toward vaccinations and boosters to combat the pandemic. However, waning immunity against SARS-CoV-2 wild-type (WT) and variants have been widely reported. Booster vaccinations have shown to be able to increase immunological protection against new variants; however, the protection observed appears to decrease quickly over time suggesting a second booster shot may be appropriate. Moreover, heterogeneity and waning of the immune response at the individual level was observed suggesting a more personalized vaccination approach should be considered. To evaluate such a personalized strategy, it is important to have the ability to rapidly evaluate the level of neutralizing antibody (nAbs) response against variants at the individual level and ideally at a point of care setting. Here, we applied the recently developed cellulose pulled-down virus neutralization test (cpVNT) to rapidly assess individual nAb levels to WT and variants of concerns in response to booster vaccination. Our findings confirmed significant heterogeneity of nAb responses against a panel of SARS-CoV-2 variants, and indicated a strong increase in nAb response against variants of concern (VOCs) upon booster vaccination. For instance, the nAb response against current predominant omicron variant was observed with medians of 88.1% (n = 6, 95% CI = 73.2% to 96.2%) within 1-month postbooster and 70.7% (n = 22, 95% CI = 66.4% to 81.8%) 3 months postbooster. Our data show a point of care (POC) test focusing on nAb response levels against VOCs can guide decisions on the potential need for booster vaccinations at individual level. Importantly, it also suggests the current booster vaccines only give a transient protective response against some VOC and new more targeted formulations of a booster vaccine against specific VOC may need to be developed in the future. IMPORTANCE: Vaccination against SARS-CoV-2 induces protection through production of neutralization antibodies (nAb). The level of nAb is a major indicator of immunity against SARS-CoV-2 infection. We developed a rapid point-of-care test that can monitor the nAb level from a drop of finger stick blood. Here, we have implemented the test to monitor individual nAb level against wild-type and variants of SARS-CoV-2 at various time points of vaccination, including post-second-dose vaccination and postbooster vaccination. Huge diversity of nAb levels were observed among individuals as well as increment in nAb levels especially against Omicron variant after booster vaccination. This study evaluated the performance of this point-of-care test for personalized nAb response tracking. It verifies the potential of using a rapid nAb test to guide future vaccination regimens at both the individual and population level. National Medical Research Council (NMRC) National Research Foundation (NRF) Published version The study is funded by National Health Innovation Singapore (NHIC) grant # NHICCOVID19-2005004, National Research Foundation via CREATE grant to Antimicrobial Resistance Interdisciplinary Research Group (AMR-IRG) of Singapore-MIT Alliance in Research and Technology (SMART). We want to acknowledge the Singapore Ministry of Health’s National Medical Research Council COVID-19 Research Fund: COVID19RF-0008 which supports the National Centre of Infectious Diseases (NCID) to provide the samples.

There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic’s changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type, alpha, beta, gamma, and delta variant receptor binding domains. It captures a clinically relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1st dose and post 2nd dose vaccination samples within 10 minutes. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a post-vaccinated population.

Neutralizing antibodies (NAbs) prevent pathogens from infecting host cells. Detection of SARS-CoV-2 NAbs is critical to evaluate herd immunity and monitor vaccine efficacy against SARS-CoV-2, the virus that causes COVID-19. All currently available NAb tests are lab-based and time-intensive. We develop a 10 min cellulose pull-down test to detect NAbs against SARS-CoV-2 from human plasma. The test evaluates the ability of antibodies to disrupt ACE2 receptor—RBD complex formation. The simple, portable, and rapid testing process relies on two key technologies: (i) the vertical-flow paper-based assay format and (ii) the rapid interaction of cellulose binding domain to cellulose paper. Here we show the construction of a cellulose-based vertical-flow test. The developed test gives above 80% sensitivity and specificity and up to 93% accuracy as compared to two current lab-based methods using COVID-19 convalescent plasma. A rapid 10 min cellulose based test has been developed for detection of NAb against SARS-CoV-2. The test demonstrates comparable performance to the lab-based tests and can be used at Point-of-Care. Importantly, the approach used for this test can be easily extended to test RBD variants or to evaluate NAbs against other pathogens. In response to infections, the human body produces proteins called antibodies. Neutralizing antibodies (NAbs) are one type of such proteins that are capable of inactivating the target, such as the SARS-CoV-2 virus that causes COVID-19. Monitoring levels of NAb allows us to understand levels of protective immunity. However, current methods to measure NAb are laboratory-based and are not necessarily suitable for large scale NAb monitoring in a large population. We develop a rapid test to detect SARS-CoV-2 NAb in 10 min that can be operated outside a laboratory. Our test provides results that are comparable to lab-based tests, which require between 1 h and up to 2 days to get a result. Our test may be useful for large-scale monitoring of immunity, for example in populations that do not have routine access to a lab. Kongsuphol et al. develop a paper-based, vertical flow assay to detect SARS-CoV-2 neutralizing antibodies. The point-of-care assay has comparable performance to lab-based tests and provides results in 10 min.

There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population. Ministry of Health (MOH) National Medical Research Council (NMRC) National Research Foundation (NRF) Published version This study is supported by National Health Innovation Singapore (NHIC) grant # NHIC-COVID19-2005004, National Research Foundation via CREATE Share grant #R571-002-021-592 and the Anti-microbial Resistance Interdisciplinary Research Group (AMR-IRG) of Singapore-MIT Alliance in Research and Technology (SMART). All samples acquired from National Centre for Infectious Diseases (NCID) were supported by Singapore Ministry of Health's National Medical Research Council COVID-19 Research Fund: COVID19RF-0008.

“Clickable” nanowires with well-defined and uniform structures made of conjugated polyfluorene polymers were successfully fabricated by single particle nanofabrication technique (SPNT). Poly[(9,9-dihex-5-yn-1-ylfluorenyl-2,7-diyl)-co-(9,9′-di-n-octylfluorenyl-2,7-diyl)] (F6E8) and poly[(9,9-dihex-5-yn-1-ylfluorenyl-2,7-diyl)-co-(2,2′-bithiophene)] (F6E2T) underwent an efficient cross-linking reaction upon irradiation, resulting in formation of one-dimensional nanostructures with high and desired aspect ratio reaching up to 200. Alkyne groups on the surface of nanowires were functionalized effectively by click reaction with fluorescent 5-TAMRA-PEG3-azide, which was confirmed by confocal microscopy. Substrates functionalized with the nanowires provide dramatic expansion of “clickable” surface area immobilized directly with TAMRA, and the fluorescence resonance energy transfer (FRET) processes between TAMRA and nanowire backbones are demonstrated as biological sensing platforms.

The preparation of photoresponsive polymer nanowires comprising photochromic azobenzene (Azo) and π-conjugated fluorene (FO) units is reported. Well-defined and uniform nanowires of the copolymer (PFOAzo) were successfully fabricated by the single particle nanofabrication technique after optimizing the FO:Azo ratio and the development conditions. Azo units in the PFOAzo nanowires underwent reversible trans–cis–trans isomerization upon exposure to ultraviolet or visible light, leading to changes in the radius (between ca. 6 and 8 nm) and morphology (straight or wavy) of the nanowires. The oligo(alkylfluorene) units in the backbone are found to profit the crosslinking efficiency upon high-energy ion beam irradiation, and more importantly, provide sufficient flexibility to allow reversible photoswitching. This demonstration of the photoluminescence, semiconducting, and mechanical properties of the PFOAzo nanowires is an important advance in the evolution of electro-mechanical nanomaterials.